Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines

British Journal of Cancer

Volumn 76, Issue 1, 1997, Pages 77-82

  Ottone, F ^a   Miotti, S ^a   Bottini, C ^a   Bagnoli, M ^a   Perego, P ^a   Colnaghi, M I ^a   Menard S ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cisplatin; Folate receptor; Ovarian carcinoma

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; FOLATE BINDING PROTEIN;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA TRANSFECTION; DRUG CYTOTOXICITY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0030916965     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.339     Document Type: Article

References (42)

1. Andrews PA and Howell SB (1990) Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2: 35-43
2. Andrews PA, Murphy MP and Howell SB (1987) Metallothionein-medialed cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 19: 149-154
3. Andrews PA, Jones JA, Varki NM and Howell SB (1990) Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun 2: 93-100
4. Antony AC (1992) The biological chemistry of folate receptors. Blood 79: 2807-2820
5. Antony AC, Kane MA, Krishnan SR, Kincade RS and Verma RS (1989) Folate (pteroylglutamate) uptake in human red blood cells, erythroid precursors and KB cells at high extracellular folate concentrations. Biochem J 260: 401-411
6. Berchunck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, McKenzie S, Yin S and Bast RC JR (1990) Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087-4091
7. Bottero F, Tomassetti A, Canevari S, Miotti S, Ménard S and Colnaghi MI (1993) Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res 53: 5791-5796
8. Boltero F, Tomassetti A, Miotti S, Colnaghi MI and Canevari S (1995) Relevance of SER234 on functionality on the high affinity folate receptor. FEBS Lett 95: 31.3
9. Branda RF and Blickensderfer DB (1993) Folate deficiency increases genetic damage caused by alkylating agents and gamma-irradiation in Chinese hamster ovary cells. Cancer Res 53: 5401-5408
10. Campbell IG, Jones TA, Foulkes WD and Trowsdale J (1991) Folate-binding protein is a marker for ovarian cancer. Cancer Res 51: 5329-5338
11. Coney LR. Tomassetti A, Carayannopoulos L, Frasca V, Kamen BA, Colnaghi MI and Zurawski VR (1991) Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res 51: 6125-6132
12. Dall'Agnese L, Viel A, Capozzi E and Boiocchi M (1995) The methylenetetrahydrofolate reductase gene mapping on 1p36.3 is frequently deleted in ovarian carcinoma. Tumori 81: 366
13. Eastman A and Schulte N (1988) Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry 27: 4730-4734
14. Foulkes WD, Campbell IG, Stamp GWH and Trowsdale J (1993) Loss of heterozygosity and amplification on chromosome 11q in human ovarian cancer. Br J Cancer 67: 268-273
15. Gross RB and Scanlon KJ (1986) Amino acid membrane transport properties of L1210 cells resistant to cisplatin. Chemioterapia V: 37
16. Henderson GB (1990) Folate-binding proteins. Annu Rev Nutr 10: 319-335
17. Jekunen AP, Hom DK, Alcaraz JE, Eastman A and Howell SB (1994) Cellular pharmacology of dichloro(ethylenediamine)platinum(II) in cisplatin-sensitive and resistant human ovarian carcinoma cells. Cancer Res 54: 2680-2687
18. Kamen BA and Capdevila A (1986) Receptor-mediated folate accumulation is regulated by the cellular folate content. Proc Natl Acad Sci USA 83: 5983-5987
19. Kane MA, Elwood PC, Portillo RM, Antony AC, Najfeld V and Finley A (1988) Influence on immunoreactive folate-binding proteins of extracellular folate concentration in cultured human cells. J Clin Invest 81: 1398-1406
20. Loh SY, Mistry P, Kelland LR, Abel G and Harrap KR (1992) Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br J Cancer 66: 1109-1115
21. Lu Y, Han J and Scanlon KJ (1988) Biochemical and molecular properties of cisplatin-resistant A2780 cell grown in folinic acid. J Biol Chem 263: 4891-4894
22. Masuda H, Ozols RF. Lai G-M. Fojo A, Rothenberg M and Hamilton TC (1988) Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines. Cancer Res 48: 5713-5716
23. Matsue H, Rothberg KG, Takashima A, Kamen BA, Anderson RGW and Lacey SW (1992) Folate receptor allows cells to grow in low concentrations of 5-methyltetrahydrofolate. Proc Natl Acad Sci USA 89: 6006-6009
24. Miotti S. Canevari S, Ménard S, Mezzanzanica D, Porro G, Pupa SM, Regazzoni M, Tagliabue F. and Colnaghi MI (1987) Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 39: 297-303
25. Miotti S, Alberti S, Facheris P, Mantovani L, Fornaro M, Stella M, Ménard S, Canevari S and Colnaghi MI (1992) Membrane association and shedding of the GPI-anchored Ca-MOv 18 antigen in human ovary carcinoma cells. Int J Cancer 51: 499-505
26. Miotti S, Facheris P, Tomasselti A, Bottero F, Bottini C, Ottone F, Colnaghi MI, Bunni MA, Priest DG and Canevari S (1995) Growth of ovary carcinoma cell lines at physiological folate concentration: effect on folate binding protein expression in vitro and in vivo. Int J Cancer 63: 395-401
27. Misawa T, Kikkawa F, Maeda O, Obata NH, Higashide K, Suganuma N and Tomoda Y (1995) Establishment and characterization of acquired resistance to platinum anticancer drugs in human ovarian carcinoma cells. Jpn J Cancer Res 86: 88-94
28. Mistry P, Kelland LR, Abel G, Sidhar S and Harrap KR (1991) The relationships between glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 64: 215-220
29. Morrow CS and Cowan KH (1990) Glutathione-S-transferases and drug resistance. Cancer Cells 2: 15-22
30. Nakagawa M, Nomura Y, Kohno K, Ono M, Mizoguchi H, Ogata J and Kuwano M (1993) Reduction of drug accumulation in cisplatin-resistant variants of human prostatic cancer PC-3 cell line. J Urol 150: 1970-1973
31. Newman EM, Lu Y, Kashani-Sabet M, Kesavan V and Scanlon KJ (1988) Mechanisms of cross-resistance to methotrexate and 5-fluorouracil in an A2780 human ovarian carcinoma cell subline resistant to cisplatin. Biochem Pharmacol 37: 443-447
32. Ozols RF (1992) Ovarian cancer. Part II: Treatment. Curr Probl Cancer 16: 67-126
33. Ozols RF and Young RC (1991) Chemotherapy of ovarian cancer. Semin Oncol 18: 222-232
34. Rosenberg B (1985) Fundamental studies with cisplatin. Cancer 55: 2303-2316
35. Scanlon KJ and Kashani-Sabet M (1988) Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells. Proc Natl Acad Sci USA 85: 650-653
36. Scanlon KJ, Newman EM, Lu Y and Priest DG (1986) Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83: 8923-8925
37. Scanlon KJ, Kashani-Sabet M, Miyachi H, Sowers LC and Rossi J (1989a) Molecular basis of cisplatin resistance in human carcinomas: model systems and patients. Anticancer Res 9: 1301-1312
38. Scanlon KJ, Kashani-Sabet M and Miyachi H (1989b) Differential gene expression in human cancer cells resistant to cisplatin. Cancer Invest 7: 581-587
39. Shionoya S, Lu Y and Scanlon KJ (1986) Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-diamminedichloroplatinum(II). Cancer Res 46: 3445-3448
40. HI® and growth inhibition of cells with HER2/neu gene amplification. Int J Cancer 47: 933-937
41. Tedeschi M, Bohm S, Di Re F, Oriana S, Spatti GB, Tognella S and Zunino F (1990) Glutathione and detoxification. Cancer Treat Rev 17: 203-208
42. Tosi E, Valota O, Negri DRM, Adobati E, Mazzoni A, Meazza R, Ferrini S, Colnaghi MI and Canevari S (1995) Anti-tumor efficacy of an anti-epidermal growth factor receptor munoclonal antibody and its F(ab′)2 fragment against high- and low-EGFR-expressing carcinomas in nude mice. Int J Cancer 62: 643-650